{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:05:35Z","timestamp":1775883935244,"version":"3.50.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This report presents the case of a patient with drug-resistant epilepsy. Despite treatment with 4 antiepileptic drugs, the patient experienced an increasing frequency of focal seizures, necessitating hospitalization, and continuous intravenous midazolam infusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Cobicistat was introduced as a pharmacokinetic booster to decrease the metabolic clearance of midazolam, leading to increased exposure and an extended half-life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Cobicistat boosting allowed the switch from intravenous to oral midazolam, and the patient was discharged on an oral midazolam regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cobicistat can be effectively used to boost midazolam exposure pharmacokinetically in patients with drug-resistant epilepsy who require stable midazolam blood concentrations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001283","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:00:10Z","timestamp":1732114810000},"page":"193-195","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Midazolam Boosting With Cobicistat in a Patient With Drug-Resistant Epilepsy and Focal Status Epilepticus"],"prefix":"10.1097","volume":"47","author":[{"given":"Tessa","family":"van den Born-Bondt","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Westra","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Krzywicka","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmen R.","family":"Moes","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Schuls-Fouchier","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/bdd.2510070108","article-title":"Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration","volume":"7","author":"Jochemsen","year":"1986","journal-title":"Biopharm Drug Dispos"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF00562804","article-title":"The pharmacokinetics of midazolam in man","volume":"19","author":"Smith","year":"1981","journal-title":"Eur J Clin Pharmacol."},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/clpt.2009.228","article-title":"Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity","volume":"87","author":"Mathias","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10928-020-09704-1","article-title":"Composite midazolam and 1\u2032-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity","volume":"47","author":"Wiebe","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-014-0223-5","article-title":"Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid","volume":"54","author":"Jullien","year":"2015","journal-title":"Clin Pharmacokinet."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:00:37Z","timestamp":1741964437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001283","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"2024-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}